Sign in

    Niels Granholm-Leth

    Research Analyst at Carnegie

    Niels Granholm-Leth is Head of Equity Research at Carnegie Investment Bank, where he specializes in coverage of Nordic healthcare and medical technology companies including Ambu, Coloplast, and Demant. Granholm-Leth is known for his detailed sector analysis and is frequently cited for his insights on company performance and market developments, though specific public metrics on his investment calls or rankings are limited. Having begun his career in finance in the early 2000s, he has held senior roles within Carnegie and also serves as Chairman of the Accounting Board of the Danish Financial Society, reflecting his focus on research quality and integrity. His professional credentials include leadership in research standards, and he is recognized for his broader influence in shaping Danish equity research.

    Niels Granholm-Leth's questions to GNNDY leadership

    Niels Granholm-Leth's questions to GNNDY leadership • Q2 2024

    Question

    Asked about future divestment plans, the outlook for net working capital release in H2, and specifics regarding the recent retail divestment.

    Answer

    The company will continue its strategy of opportunistic, non-core divestments but is not in a rush. They expect a positive net working capital impact for the full year, driven by improvements in H2, including benefits from the consumer wind-down. Details on the wholesale agreement with the divested retail business were not provided.

    Ask Fintool Equity Research AI